Over the past few decades, the human epidermal growth factor receptor (EGFR) has been established as an attractive target for non-small cell lung cancer (NSCLC) therapy. Nevertheless, the approved EGFR inhibitors, gefitinib or erlotinib have shown minimum clinical activity to breast cancer patients, who also highly expressed EGFR. In this study, we designed and synthesized a series of novel formononetin derivatives by reference to the binding mode of lapatinib to EGFR. 
Introduction
The epidermal growth factor receptor (EGFR) is a transmembrane protein, belonging to the family of tyrosine kinases and involved in cell proliferation and signal transduction.
1 It has been conrmed that EGFR is highly or abnormally expressed in many solid tumors and is correlated to tumor cell proliferation, angiogenesis, tumor invasion, metastasis, and inhibition of apoptosis. 2, 3 Over-expression of EGFR is also crucial for the evolution of malignant tumors, such as glioma cell, kidney, lung, breast, prostate and pancreatic cancer. [4] [5] [6] The activation of EGFR phosphorylates its downstream signalling molecules PI3K and Akt, which are involved in cellular migration, apoptosis and mitogen-activated protein kinase signalling, Ras/Raf/MEK/ERK, as implicated in cell proliferation. 7, 8 It is well known that inhibition of EGFR kinasemediated signal is a well-established strategy for the treatment of advanced stage non-small cell lung cancer (NSCLC) and also correlated well with the proliferation and migration of aggressive triple negative breast cancer, MDA-MB-231.
9,10
Studies have shown that triple-negative breast cancer was considered another potential indication for EGFR kinase inhibitors because they are not amenable to endocrine or HER-2 targeted therapies, while they highly-express EGFR kinase.
10,11
Some literatures have suggested a crucial role of EGFR in breast cancer proliferation and migration. However, inhibition of EGFR by getinib or erlotinib showed low efficacy in arresting tumor cell growth at the cell line level and minimum clinical activity. 7, 12 Such extraordinary phenomenon always attracts us to explore the underlying mechanism and discover new potent EGFR inhibitors that are naturally derived chemicals as breast cancer therapeutics.
Natural products are a major source of drug discovery and cancer therapy. Formononetin (Fig. 1) is a bioactive isoavone found in diverse Chinese medicine herbals, such as Amorpha fruticose, 13 Glycyrrhiza, 13, 14 Trifolium pretense, 13, 14 Astragalus membranaceus, 15 which belonging to the family of Leguminosae. It has attracted broad attention because of multiple pharmacological activities, such as anti-bacterial, 16, 17 anti-cancer, 17 antioxidant, 18 anti-diabetic 19, 20 and anti-hyperlipidemia. 21 Currently, many formononetin analogues ( Fig. 1) were designed as anticancer agents and explored the biological mechanism against various human cancer cell lines. As reported that formononetin can induce cell apoptosis via PI3K/AKT signaling pathway in human nasopharyngeal and cervical carcinoma cells. 22 Formononetin-dithiocarbamate hybrids 8i could inhibit growth and migration of PC-3 cells via MAPK/Wnt signaling pathway and cause cell cycle arrest in G1 phase. 23 While its 7-phosphoramidate derivative 8d and nitrogen-mustard derivative 6n could induce cell cycle arrest in G2/M phase and cell apoptosis. 24, 25 In addition, Manupati et al. reported a chrysin analog CHM-09 which potentiated the mesenchymal-epithelial transition of breast cancer stem cells through inhibiting EGFR. 10 In the light of previous studies, we reported here the designation of novel formononetin derivatives as potent anticancer agents through targeting EGFR and further investigation of their underlying biological mechanisms.
Results and discussion

Chemistry
In this study, we hypothesize that the design of synthetic derivatives of formononetin against EGFR with lapatinib as positive control may improve its anticancer efficacy. Before synthesis, a molecular screening process was performed by computer assist drug design (CADD) method. Molecular docking was conducted to calculate the binding energy (CDOCKER INTERACTION ENERGY in CDOCKER protocol in Discovery Studio 3.5) between compounds and EGFR complex structure (1XKK.pdb, downloaded from the PDB). Finally, 22 compounds were picked to continue assays subsequently and their binding energy were shown in Table S1 (ESI †).
In view of the binding energy, 4v is the best one among them. For better understanding of the potential of 4v, we further examined the interaction of 4v with EGFR (PDB code 1XKK) with lapatinib as the positive control. All the amino acid residues which had interactions with lapatinib were exhibited and the results were depicted in Fig. 2A . In the binding model, lapatinib bound well to EGFR mainly via three hydrogen bonds with ARG 803, ASP 800 and PHE856, a p-cation bond with LYS 745 and a p-p bond with PHE856. In the binding model of 4v with EGFR ( Fig. 2C ), there formed a hydrogen bond with MET 793, a pcation bond with LYS 745, a p-anion bond with ASP 800, a p-p bond with PHE856 and a p-sigma bond with MET766 which are the main contributors for the effective combination between them. The 3D models of the interaction between lapatinib, 4v and EGFR were also depicted in Fig. 2B and D. For Fig. 2E , we further compared the structure and target combine similarity of 4v and lapatinib. The result demonstrated that 1c might be a potential EGFR inhibitor.
The synthetic routes of novel formononetin derivatives are outlined in Scheme 1, and structure of derivatives 4a-4v are shown in Table 1 . These compounds were obtained by three steps which were elucidated in the Experimental section. All of them are rst reported and characterized by Interactions of lapatinib with the amino acid residues at the binding pocket of EGFR (carbon atom, gray; oxygen atom, red; hydrogen atom, white; nitrogen atom, purple; chlorine atom, bright green; fluorine atom, light green; sulphur atom, orange). (B) Binding pose of lapatinib in the protein surface of EGFR (carbon atom, blue; oxygen atom, red; hydrogen atom, white; nitrogen atom, purple; chlorine atom, bright green; fluorine atom, sulphur atom, orange). Hydrogen bonds were displayed as green dashed lines. (C) Interactions of 4v with the amino acid residues at the binding pocket of EGFR (carbon atom, gray; oxygen atom, red; hydrogen atom, white; nitrogen atom, purple; sulphur atom, orange). (D) Binding pose of 4v in the protein surface of EGFR (carbon atom, blue; oxygen atom, red; hydrogen atom, white; nitrogen atom, purple; sulphur atom, orange). Hydrogen bond was displayed as green dashed lines. (E) 3D mode of the interaction between the compounds (lapatinib, brown; 4v, blue) and the EGFR binding site. The protein is represented by molecular surface.
Biological studies
In order to screen out the optimal active compounds from all synthesized formononetin derivatives, a comparative study was carried out to evaluated their in vitro EGFR inhibition activities. As shown in Table 2 , we clearly found that most of the tested compounds presented stronger EGFR inhibitory activity compared to formononetin itself. Especially, compound 4v was the most potent inhibitor of EGFR (IC 50 ¼ 14.5 nM), which was at least 10-fold stronger than formononetin (IC 50 > 150 nM) and almost comparable to getinib (IC 50 ¼ 6.2 nM) and lapatinib (IC 50 ¼ 5.6 nM). Among them, compound 4n also showed potent EGFR inhibitory activity with an IC 50 value of 20.6 nM. Generally, electron-donating group improved the enzymatic inhibitory activity more signicantly than the electronwithdrawing group, especially when the substitution appeared at the R3-position of benzene ring of formononetin skeleton.
Scheme 1 Chemical synthesis routine of 4a-4v. Reagents and conditions: (a) ethyl bromoacetate, acetone, K 2 CO 3 , reflux, 10 hours; (b) hydrazine hydrate, ethanol, reflux, 10 hours; (c) benzaldehyde, glacial acetic acid, ethanol, reflux, 6 hours. Then we further evaluated their anti-proliferation activities against four cancer cell lines, human breast cancer cells (MCF-7, MDA-MB-231), human lung carcinoma cells (H460, H1650), as well as two non-cancer cell lines, normal human liver cells (L02) and African green monkey kidney cell (VERO) by the cell based MTT assay. The results are summarized in Table 3 and expressed by the half maximal inhibitory concentration (IC 50 ) values. As shown in Table 3 , all compounds showed good anti-proliferation activity against the cancer cells, and most of them even better than formononetin itself with the standard of IC 50 values. To be specic, most compounds showed better anti-proliferation activity against MDA-MB-231 than MCF-7, which might because of the high expression of EGFR in the former. migration and metastasis through different signaling pathways. 26 To investigate the effect of 4v on signal transduction mechanism, we performed immunoblot analysis of EGFR and its downstream signaling pathways: extracellular signal regulated kinase (ERK) and Akt. As shown in Fig. 3 , MDA-MB-231 cells that express high EGFR were treated with increasing concentrations of 4v and demonstrated a dose-dependent decrease in phosphorylation of EGFR, ERK and Akt.
To further substantiate the anti-proliferative effect of 4v on MDA-MB-231 cells, we evaluated its impact on the cell cycle arrest. As illustrated in Fig The transmembrane potential (DJ m ) is an important parameter for mitochondrial functionality and its dissipation means the involvement of mitochondria in early apoptosis. 27 As shown in Fig. 5 , microscopy revealed that in untreated MDA-MB-231 cells, well-polarized mitochondria were marked by red uorescent staining. Aer treated with 2 or 4 mM of 4v, this pattern was replaced by green uorescence in MDA-MB-231 cells. CCCP was used as the positive control here. Additionally, ow cytometry results also showed that untreated cells with well-polarized, red-emitting mitochondria localized in the upper region of the plot. Cells exposed to 4v for 12 hours underwent a progressive loss of red uorescence, indicated by a downward in 4v treated groups. The ratio of cells with high membrane potential decreased from 85.2% to 80.8% aer exposed to 2 mM 4v for 12 hours and even decreased to 56.8% in 4 mM 4v treated group. Likewise, the loss of mitochondrial potential in MDA-MB-231 cells caused by 4v also showed timedependent manner.
Based on the above results, we also evaluated the apoptotic populations of MDA-MB-231 cells treated with 4v using ow cytometry analysis. As shown in Tumor cell migration has been identied as one hallmark of malignant tumor progression, particularly for the establishment of lethal secondary metastases at distant organs. To investigate whether 4v could inhibit the migratory capacity of MDA-MB-231 cells, the conventional in vitro wound healing assay was also conducted. As shown in Fig. 7A and B, the control group cells gradually occupied the cell-free space within the channel over time and the cells almost ll the channel aer 48 hours. Whereas, cells migration capacity of 4v-treated group was greatly inhibited and the inhibition was dose-dependent. The Wnt signaling pathway is crucial for multiple cellular processes including cell proliferation and migration. Once To evaluate the anti-tumor effects of 4v in vivo, we subcutaneously inoculated MDA-MB-231 cells in to the right ank of female nude mice. Two weeks later, all the mice got visible tumors. The mice were randomized into 3 groups, vehicle (olive oil), 4v (5 mg kg À1 ) and positive control (getinib, 5 mg kg À1 ; lapatinib, 5 mg kg À1 ). As shown in Fig. 8A , the administration of 4v greatly inhibited the tumor growth compared with the vehicle group and the inhibition effect was similar to that of Relative band intensity was determined by Image J software. GAPDH served as a loading control. Images are representative of three independent experiments. Data are means AE S.E.M. from three independent experiments (*P < 0.05; **P < 0.01).
lapatinib, while the traditional EGFR inhibitor getinib showed extremely low therapeutic efficiency on MDA-MB-231 cells. Aer the last time of treatment on day 21, the average weight of tumors from 4v-treated mice was nearly 2-fold less than the olive oil treated group (Fig. 8C) . Meanwhile, 4v has no signi-cant inuence on the body weight of the mice (Fig. 8B ).
Experimental
General information and materials
Formononetin (purity $ 99%), ethyl bromoacetate, hydrazine hydrate, a series of benzaldehyde with different substituents, acetic acid, acetone, ethanol, etc. According to experimental conditions, all reagents used were of analytical reagent grade (AR) except ethanol which was puried and purchased from Nanjing Chemical Reagent Co. Ltd. (Nanjing, China). Getinib (purity $ 99%) and lapatinib (purity $ 99%) were purchased from J&K Scientic Ltd. (Shanghai, China 13 C NMR spectra were reported in ppm (d). The ESI-MS spectra were obtained on a Mariner Biospectrometry Workstation (ESI-TOF) mass spectrometer. Melting points of products were determined using a XT4 MP Apparatus (Taike Corp., Beijing, China) and uncorrected. TLC was carried out on the glass-backed silica gel sheets (silica gel 60Å GF254) and visualized in UV light (254 nm). Cell culture reagents were purchased from Gibco Life Technology (Grand Island, NY, USA). MTT, PMSF, and RIPA lysis buffer (#P0013B) were purchased from Beyotime Institute of Biotechnology (Haimen, China). Cell Cycle Detection Kit and Annexin V-FITC/PI apoptosis detection kit were purchased from KeyGEN Biotech Co. Ltd (Nanjing, China). Mitochondrial membrane potential assay kit with JC-1 was purchased from Beyotime Biotech Co. Ltd (Haimen, China). BCA protein assay kit (#23227) was purchased from Pierce (Rockford, IL, USA). PVDF membranes were purchased from Biosharp (Hefei, China). Anti-Axin-2 (20540-1-AP) was purchased from Proteintech (Wuhan, China); anti-cleaved PARP-1 (#sc-56196) was purchased from Santa Cruz Biotechnology Inc. (Dallas, Texas, USA). Anti-EGFR (WL0682a), anti-ERK (WL01864), anti-p-ERK (WLP1512), anti-Akt (WL0003b), anti-p-Akt (WLP001a), anti-CDK4 (WL02143), anti-Cyclin A (WL01753), anti-Cyclin D1 (WL01435a), anti-b-Actin (WL0002c), anti-Bax (WL01637), antiBcl2 (WL01556), anti-cleaved caspase-3 (WL01992), anticytochrome c (WL01571) and anti-b-catenin (WL0962a) were purchased from Wanlei Biotech Co. Ltd (Shenyang, China). GAPDH antibody (#E1A7021) and secondary antibody (anti-mouse or anti-rabbit IgG) (#E1WP319 or #E1WP318) were purchased from Enogene (Nanjing, China). ECL Kit (#34077) were purchased from Thermo Scientic (USA).
General procedure for preparation of compound 2
A mixture of formononetin (0.04 mol, 11.44 g) and potassium carbonate (0.08 mol, 22.48 g) were stirred in acetone under the condition of reux at 60 C for 3 hours to get dissolved and claried. Meanwhile, proportionable ethyl bromoacetate (0.04 mol, 4.9 g) was prepared which dissolved in appropriate acetone and added to the system dropwise to react another 10 hours. And then reaction system was ltered in hot to obtain ltrate. When the ltrate tended to be cooling, a large amount of compound 2 separated out and washed with petroleum ether, 1% sodium hydroxide and distilled water successively. The product was dried in the oven weighing 9.97 g (87% General procedure for preparation of compound 3
Compound 2 (0.025 mol, 8.85 g) was added to a clean roundbottom ask which contained 30-40 mL of ethanol. The reaction mixture was stirred under the condition of reux at 80 C. Hydrazine hydrate (0.075 mol, 3.9 g) was added and stirred for a further 10 hours with the reaction system getting claried gradually. While stirring, the product was checked with TLC continually to choose the right point in time to stop the reaction. Aer the system temperature cooling to room temperature, the compound 3 which is white was isolated by ltration when precipitated. The product was dried in the oven weighing 7.45 g (84% General procedure for preparation of compounds 4a-4v
Compounds 4a-4v were synthesized by reacting the compound 3 (0.0008 mol) with the different substituted ethyl benzaldehyde (0.0008 mol) in a Schiff base condensation reaction. The reaction was stirred at 80 C for 8 hours in the presence of a bit of glacial acetic acid (4-8 drops) in ethanol. The compounds 4a-4v were obtained by ltering aer precipitation and all structure shown in Table 1 . Anal. calcd for C 26 
EGFR kinase phosphorylation assay
The assays were carried out as described previously. C, 5 mL of each reaction was spotted on phosphocellulose P81 paper (Whatman). The P81 paper was then washed 5 times with 50 mM phosphoric acid for 15 minutes, dried, and exposed to a phosphorimager screen (Storm, GE Healthcare), which was scanned and densitometrically analyzed the next day. The sequence of the substrate peptide was derived from phospholipase C-g1. The IC 50 values were calculated using nonlinear regression with normalized dose response t using Prism GraphPad soware.
Anti-proliferation assay
The anti-proliferation activity of the prepared compounds against four cancer cell lines, MCF-7, MDA-MB-231, H460, H1650 and two normal cell lines, L02 and VERO were evaluated as described elsewhere. 29 Four kinds of cancer cell lines and two normal cell lines were plated in 96-well plates at the appropriate density (2.0 Â 10 3 cells per well) with maintained in DMEM (or 1640 medium) with 10% FBS and cultivated for 12 hours at 37 C, 5% CO 2 atmosphere. All cells treated with different concentrations (0, 0.1, 1, 10 and 100 mM) of each compound with formononetin and lapatinib as positive references. Aer 24 hours, 20 mL PBS containing of MTT solution (2.5 mg mL À1 ) was added to each well and incubated for a further 4 hours. Then 150 mL of DMSO was added to each well to dissolve purple crystal. The plates were shaken to ensure the completion solubility for 10 minutes at room temperature. The values of absorbance were recorded on ELISA reader (ELx800, BioTek, USA) at a wavelength of 570 nm. All experiments were performed in three replicate wells for each concentration of all compounds including formononetin, and all assay experiments were carried out three times. The IC 50 values dened as the concentrations that cause a 50% loss of cell viability were calculated by Origin 7.5 and exhibited in Table 3 .
Apoptosis analysis by ow cytometry
Cell apoptosis assay of compound 4v for MDA-MB-231 cell was carried out by Annexin V/PI assays and monitored by ow cytometry. Briey, 5 Â 10 3 cells per well were seeded in 6-well plates for 12 hours and then treated with 4v (0, 2, 4 and 8 mM) for 24 hours or treated with 4 mM 4v for 0, 12, 24 and 36 hours. Next, cells were collected and washed twice with PBS and then centrifuged to obtain sedimentation. 500 mL 1Â binding buffer (10 mM HEPES, PH 7.4, 140 mM NaOH, 2.5 mM CaCl 2 ) was added to each EP tube to make cells resuspended and stained with 5 mL of Annexin V-FITC and 5 mL of PI for 30 minutes at room temperature in the dark. Apoptotic cells were quantied using a BD Accuri C6 Flowjo Cytometer (BD, USA). Statistical analysis was done using Flowjo 7.6.1 soware.
Mitochondrial membrane potential staining
JC-1 is an ideal uorescent probe which is widely used in the detection of mitochondrial membrane potential (DJ m ). According to the requirements, MDA-MB-231 cells were cultured in 6-well plates (5 Â 10 3 cells per well) for 12 hours at 37 C, 5% CO 2 atmosphere and then treated with compound 4v were counted using the Flowjo 7.6.1 soware excluding cell debris.
Wound-healing assay
MDA-MB-231 cells were seeded in a tissue culture 6-well plate at an initial density of 2 Â 10 5 cells per cm 2 overnight. A micropipette tip was used to create a wound in the monolayer by scraping aer cells seeding and incubation for 24 hours. Identical cell-free space was observed by phase-contrast microscopy (NIKON, Japan) and digital images were taken by cells at 0, 24 and 48 hours. Subsequently, the NIH Image J image analysis soware was used to outline the wound areas and analysis quanties the reduced cell-free space, n ¼ 3.
Western blot analysis
Total proteins were extracted from MDA-MB-231 cells which were treated with compound 4v at different concentrations (0, 2, 4 and 8 mM). Cells obtained were lysed in RIPA lysis buffer containing protease inhibitor phenylmethanesulfonyl uoride (PMSF, PMSF : RIPA ¼ 1 : 100) on ice for 20-30 minutes. Protein content was measured using a Pierce BCA protein assay kit. Protein samples were separated by sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto polyvinylidene diuoride (PVDF) membranes which were blocked with 5% non-fat-milk for 1 hour. All membranes were separated and incubated with primary antibodies including EGFR (rabbit polyclonal IgG, 1 : 1000 dilution), p-EGFR (rabbit polyclonal IgG, 1 : 1000 dilution), ERK (rabbit polyclonal IgG, 1 : 500 dilution), p-ERK (rabbit polyclonal IgG, 1 : 500 dilution), Akt (rabbit polyclonal IgG, 1 : 500 dilution), p-Akt (rabbit polyclonal IgG, 1 : 500 dilution), GAPDH (rabbit polyclonal IgG, 1 : 1000 dilution), CDK4 (rabbit polyclonal IgG, 1 : 500 dilution), Cyclin A (rabbit polyclonal IgG, 1 : 500 dilution), Cyclin D1 (rabbit polyclonal IgG, 1 : 500 dilution), b-actin (rabbit polyclonal IgG, 1 : 500 dilution), Bax (rabbit polyclonal IgG, 1 : 500 dilution), Bcl2 (rabbit polyclonal IgG, 1 : 500 dilution), cleaved caspase-3 (rabbit polyclonal IgG, 1 : 500 dilution), cleaved-PARP (mouse monoclonal IgG, 1 : 600 dilution), cytochrome c (rabbit polyclonal IgG, 1 : 500 dilution), b-catenin (rabbit polyclonal IgG, 1 : 500 dilution) and Axin-2 (rabbit polyclonal IgG, 1 : 1000 dilution) at 4 C shaking overnight. Aer the membrane was washed three times with tris-buffered saline buffer, HRP-conjugated secondary antibody (diluted 1 : 50 000) was used at room temperature. Detection was performed by an enhanced chemiluminescent reagent (Thermo Fisher Scientic, USA) according to the manufacturer's instructions. Bands were then recorded by a digital camera (Tanon 5200, Tanon, China). Finally, the results were analyzed with Image J Soware (National Institutes of Health, BetheSEMa, Maryland, USA), and all the targeted protein were normalized to GAPDH or b-actin.
Transplantation of MDA-MB-231 cells into nude mice
Cultured MDA-MB-231 cells were washed with and resuspended in ice-cold PBS. Portions of the suspension (6 Â 10 6 cells in 0.1 mL) were injected into the right anks of female nu/nu mice. Two weeks aer the injection, the mice bearing tumors (an average size of 90 mm 3 ) were distributed into 3 groups (n ¼ 8 mice per group) according to tumor volumes. 4v (5 mg kg À1 ) and lapatinib (5 mg kg À1 ) were dissolved in olive oil and administered once every two days for 11 times by intraperitoneal injection. Vehicle (olive oil)-treated group was included as control. Body weight and tumor volumes were measured and recorded every two days. Long diameter (L) and short diameter (S) of a tumor were measured with a vernier caliper and the tumor volume was calculated using the following formula: L Â (S) 2 /2. Twenty-one days aer injection, the mice were killed and tumors were separated. Tumor weight was measured and tumor sections were xed in paraformaldehyde. The rest of the sections were frozen in liquid nitrogen and stored at À80 C.
Data and statistical analysis
All experiments were repeated at least three times. Data are presented as mean AE S.E.M. and statistical comparisons between the treated and untreated groups were performed using one-way ANOVA using GraphPad PRISM5 (Graphpad Inc., La Jolla, USA). P-Values of <0.05 were considered statistically signicant; P-values of <0.01 were considered statistically very signicant.
Conclusion
In this study, a series of novel formononetin derivatives targeting EGFR kinase were designed, synthesized and evaluated for their potential anti-proliferation activities against human breast and lung cancer cell lines. 
